Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis.
Hannah den BraankerKim WerversAdriana M C MusPriyanka S BangoerNadine DavelaarJolanda LuimeIlja TchetverikovJ M W HazesMarijn VisErik LubbertsMarc R KokPublished in: RMD open (2021)
Our results showed that only 18% of patients with PsA are in sustained MDA after 1 year of MTX monotherapy and non-responders more often had IL-23-driven disease. Our results indicate the need for more treat-to-target and personalised therapy strategies in PsA.
Keyphrases
- disease activity
- prostate cancer
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- radical prostatectomy
- high dose
- randomized controlled trial
- open label
- breast cancer cells
- clinical trial
- mesenchymal stem cells
- low dose
- cell death
- bone marrow
- cell proliferation
- signaling pathway
- study protocol